ACCREDITATION
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this educational activity for a maximum of 110 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society's Annual Meeting Steering Committee (AMSC). The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations.
DISCLAIMER
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.
LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
- Discuss state-of-the-art research in endocrinology
- Demonstrate updated knowledge of the pathophysiology, diagnosis, and treatment of diabetes, obesity, cardiovascular disease, dyslipidemia and adrenal, metabolic, bone, pediatric, pituitary, thyroid, and reproductive endocrine disorders
- Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae
- Apply updated knowledge and clinical skills in improving patient care
TARGET AUDIENCE
This continuing medical education activity should be of substantial interest to: Endocrinologists, pediatric endocrinologists, reproductive endocrinologists, internists, clinical researchers and other endocrine professionals
RELEASE DATE: September 1, 2010
TERMINATION DATE: September 1, 2011
DISCLOSURE POLICY
The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty or others with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty and committee members reported relevant financial relationships, as identified below:
LP Aiello: Consultant, Eli Lilly & Co, Genentech, Inc., Genzyme Corporation, Merck & Co, Novartis Pharmaceuticals, Pfizer, Inc; Advisory Group Member, Genentech, Inc., Genzyme Corporation; AF Attanasio: Consultant, Lilly USA, LLC; JP Bilezikian: Consultant, Amgen, Lilly USA, LLC, NPS; Speaker, Lilly USA, LLC; R Bouillon: Speaker, Amgen, Merck & Co; Researcher, Lilly USA, LLC, Tibotec; PJ Boyle: Speaker, Amylin Pharmaceuticals; Speaker Bureau Member, Lilly USA, LLC, Takeda; GD Braunstein: Consultant, Acrux Australia, Abbott Laboratories; Principal Investigator, BioSante; E Brinton: Speaker Bureau Member, Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Merck & Co., Takeda; Study Investigator, Merck & Co.; Principal Investigator, Abbott Laboratories; Consultant, Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Merck & Co., Takeda; MS Brose: Principal Investigator, Bayer, Inc., Novartis Pharmaceuticals; Speaker, Bayer, Inc.; Study Investigator, Exelixis, Daichi-Sanyo; Research Funding, Onyx; M Brown: Consultant, Novartis Pharmaceuticals; Collaborator, Novartis Pharmaceutical; KD Burman: Investigator, Pfizer, Inc., Exelixis; SD Chernausek: Consultant, Ipsen; Coinvestigator, Nestle; PE Clayton: Principal Investigator, Serono, Ipsen; JE Compston: Advisory Group Member, Amgen, Novartis Pharmaceuticals; Speaker, Procter & Gamble, Lilly USA, LLC; K Cusi: Speaker Bureau Member, Abbott Laboratories, Astra Zeneca, Merck & Co.; Principal Investigator, Amylin, Eli Lilly & Co., Takeda; SE Dagogo-Jack: Consultant, Lilly USA, LLC, GlaxoSmithKline, Merck & Co., Roche Pharmaceuticals; PB Duell: Speaker, Consultant, GlaxoSmithKline; EA Eugster: Study Investigator, Abbott Laboratories; Medical Advisory Board Member, ENDO Pharmaceutical; JA Fagin: Medical Advisory Board Member, Astra Zeneca, Novo Nordisk; Principal Investigator, Novo Nordisk; K Feingold: Speaker, Amylin Pharmaceuticals, Lilly USA, LLC, Abbott Laboratories, AstraZeneca, Merck & Co., Takeda, Bristol-Myers Squibb; Principal Investigator, Merck & Co; GL Francis: Owner, Amgen, Genentech, Inc; P Freda: Investigator, Novartis Pharmaceuticals, Ipsen, Pfizer, Inc; S Genuth: Owner, Johnson & Johnson, GlaxoSmithKline; Coinvestigator, Novartis Pharmaceuticals; CM Gordon: Associate Director, Harvard/MIT and Pfizer/Merck; Sponsored Fellowship Training Program, Pfizer, Inc; TA Guise: Advisory Group Member, Amgen, Roche Diagnostics, Novartis Pharmaceuticals; Speaker, Amgen, Lilly USA, LLC, Novartis Pharmaceuticals, Owner, Amgen; IB Hirsch: Consultant, Johnson &Johnson, Roche Diagnostics; K Ho: Advisory Group Member, Eli Lilly and Company, Merck & Co.; Speaker, Pfizer Global R&D; Consultant, Ipsen; Research Funding, Novartis Pharmaceuticals; MF Holick: Speaker, Merck & Co., Sanofi-Aventis, Novartis Pharmaceuticals, Amgen, Procter & Gamble; Consultant, Bayer, Inc; G Johannsson: Advisory Group Member, Altus Pharmaceuticals, Pfizer, Inc.; Ad Hoc Consultant, Novo Nordisk; Speaker, Novo Nordisk, Pfizer, Inc.; Clinical Researcher, Novo Nordisk, Pfizer, Inc.; Chief Scientific Officer, DuoCort Pharma AB; LM Kaplan: Principal Investigator, Merck & Co., GI Dynamics, Johnson &Johnson, Arena; Consultant, Davol, Inc.; Scientific Board Member, Gelesis; Consultant, Medtronic; R Klein: Advisory Group Member, AstraZeneca, Takeda; Consultant, Genentech, Inc., GlaxoSmithKline, Pfizer, Inc.; A Klibanski: Principal Investigator, Pfizer, Inc; RT Kloos: Coinvestigator, Esai, Exelixis; MT Korytkowski: Consultant, Lilly USA, LLC; Grant Review Panel, Pfizer, Inc.; JM Lane: Speaker, Lilly USA, LLC, Novartis Pharmaceuticals, Sanofi-Aventis; JL Leahy: Medical Advisory Board Member, Merck & Co., Novo Nordisk, Sanofi-Aventis; Speaker, Merck & Co., Sanofi-Aventi; Consultant, Sanofi-Aventis.; N Mauras: Study Investigator, Genentech, Inc.; Investigator, Pfizer, Inc; PD Miller: Scientific Board Member, Amgen, Lilly USA, LLC; Speaker Bureau Member, Genentech, Inc., Aventis Pharmaceuticals, Novartis Pharmaceuticals; ME Molitch: Investigator, Corcept, Inc.; JW Newcomer: Consultant, AstraZeneca, Jansen Pharmaceuticals, Organon Laboratories, Pfizer, Inc., Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Bristol-Myers Squibb, H. Lundbeck, Otsuka Pharmaceuticals, Vanda Pharmaceutical; DSMC Member, Organon Laboratories, Schering Plough, Vivus USA, Dainippon Sumitomo Pharma America, Inc.; Data Safety Monitoring Committee Compact Clinicals, Vivus, Inc.; Product Development, Jones and Bartlett Publishing.; JDC Newell-Price: Investigator and Advisory Group Member, Novartis Pharmaceuticals; SW Ponder: Consultant, Diabetech, LLP; RE Ratner: Owner, Abbott Laboratories, ConAgra Foods, Johnson &Johnson, Merck & Co.; Principal Investigator, Amylin Pharmaceuticals, Aventis Pharmaceuticals, GlaxoSmithKline; Scientific Board Member, Novo Nordisk, Roche Pharmaceuticals.; RJM Ross: Director, Asterion Ltd, Diurnal Ltd.; R Salvatori: Advisory Group Member, Novo Nordisk; Researcher, Novo Nordisk; C Sawyers: Coinventor, Medivation; SI Sherman: Investigator, Amgen, AstraZeneca, Genzyme Corporation; Advisory Group Member, AstraZeneca; Consultant, Bayer, Inc., Celgene, Lilly USA, LLC, Oxigene, Exelixis, Plexxikon, Semafore.; Speaker, Genzyme Corporation; RM Tuttle: Consultant, Abbott Laboratories, Genzyme Corporation; AI Vinik: Study Investigator, Abbott Laboratories, Johnson &Johnson, Pfzer, Inc.; Speaker Bureau Member, GlaxoSmithKline, Merck & Co., Sanofi-Aventis, Tercic; AB: Consultant, Tolerx; Inventor, Nutrinerve.; SM Webb: Speaker, Novartis Pharmaceuticals; Study Investigator, Novartis Pharmaceuticals.
The following faculty and committee members reported no relevant financial relationships:
M Ader; RA Adler; V Aguirre; SF Ahmed; BD Anawalt; CM Apovian; BM Arafah; W Arlt; G Arnaldi; AB Atkinson; RJ Auchus; R Azziz; LK Bachrach; A Belgorosky; VJ Bernet; S Bhasin; DD Bikle; MM Bliziotes; S Bornstein; P-MG Bouloux; MJ Brady; GA Brent; MD Bronstein; KD Burman; D Calebiro; AR Cappola; ML Caramori; E Carmina; PC Chandler-Laney; VM Chesnokova; JE Compston; JM Connell; GS Conway; DM Cook; DS Cooper; MS Cooper; G Corona; MA Corson; GR Cunha; WW de Herder; MD DeBoer; R Di Lauro; C Dode; HM Domene; RW Downs; C Dulac; DA Ehrmann; GS Eisenbarth; R Elisei; SR Farmer; M Fassnacht; E Gale; JC Gallagher; MP Gallagher; A Garg; H Gharib; V Goffin; PJ Goodwin; ME Gottschalk; D Grammatopoulos; MC Greenlee; RJ Grekin; LC Groop; AB Grossman; M Grossmann; JE Hall; BR Haugen; FJ Hayes; MW Haymond; VW Henderson; JV Hennessey; JM Hershman; AG Herzog; M Hewison; K Ho; SP Hodak; KM Hoeger; MJ Horwitz; IM Hramiak; ESverre Husebye; V Hwa; KL Insogna; SM Jan De Beur; TH Jones; J Jonklaas; L Jovanovic; BB Kahn; EM Kaptein; S Khosla; W Kiess; HH Kim; RH Knopp; AC Latronico; LC Layman; RS Legro; MB Leonard; MA Levine; JE Levine; RS Lindsay; M Maghnie; DM Maiter; SJ Mandel; DJ Mangelsdorf; JE Manson; KA Martin; LR McCabe; AL McCall; CR McCartney; MT McDermott; B McIver; RI McLachlan; AR McLellan; GT McMahon; S Melmed; M Mercado; KK Miller; JP Monson; S Mudaliar; RM Myers; LB Nachtigall; R Nass; EF Nemeth; RC Nicholson; LK Nieman; CB Niewoehner; YE Nikiforov; RJ Norman; JM Olefsky; E Oral; KG Osteen; K Pacak; MR Palmert; SB Patel; JM Pettifor; L Philipson; JD Piette; N Pitteloud; WE Rainey; N Rasgon; RE Ratner; JB Redmon; RP Robertson; G Rodgers; CJ Rosen; SM Rosenthal; W Rosner; DS Ross; BS Rubin; DE Sandberg; P Sassone-Corsi; S Sathyanarayana; JA Schlechte; PJ Schmidt; D Sellmeyer; DM Shoback; RA Simmons; PA Singer; R Smith; PW Speiser; A Stagnaro-Green; KS Steinbeck; D Steinberg; ES Strotmeyer; B Swearingen; RS Swerdloff; LR Tannock; MO Thorner; S Thurston; GH Van den Berghe; G Van Vliet; HW Vesper; AN Vgontzas; CC Wang; JA Wass; ME Wierman; FC Wu; BB Yeap; D Yee; J Young; M Zitzmann
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
All disclosures have been checked against forms submitted by faculty, planners and Endocrine Society staff as appropriate.
CONFLICT OF INTEREST STATEMENT
The scientific content of this activity was developed by The Endocrine Society's Annual Meeting Steering Committee, independent of grant support and in accordance with the ACCME's Essential Areas and Elements, including the Standards for Commercial Support. The commercial supporters of this meeting have no influence over topics or speakers.
POLICY ON UNLABELED/OFF-LABEL USAGE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial products is informative for audiences and therefore requires that speakers disclose this information to the learners at the beginning of the presentations.
Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY & CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Abbott Laboratories, Corcept Therapeutics, and Lilly USA, LLC.
METHOD OF PARTICIPATION
This enduring material is presented in an online/computer-based format. System requirements include:
- For Windows, Firefox 1.5 or Internet Explorer 6.0 with Flash 8 or better installed.
- For Macintosh OS X, Safari 2.0 or Firefox 1.5 with Flash 8 or better installed.
To receive AMA PRA Category 1 Credits™, the learner should:
- Select a session and listen to the audio and/or view the slides.
- Complete the evaluation provided at the end of the session and click on "submit" to add the session to the learner's transcript. The transcript will appear and the learner will have the option of printing a CME certificate then or at a later time, after viewing multiple sessions.
- Select additional sessions and proceed as directed above, to accumulate credits for participating in multiple sessions.
- Credits awarded correspond to the length of time for each session, which varies from 0.5 to 0.75 hour.
For technical assistance or information, please contact Content Management Corporation at 972-910-6899 (9:00 AM to 5:00 PM EST or multiviewMediaSupport@multiview.com.
For questions regarding CME content or obtaining CME credit, please contact The Endocrine Society at 301.941.0200 or amcelvaine@endo-society.org.